Literature DB >> 26595642

Lewy body dementias.

Zuzana Walker1, Katherine L Possin2, Bradley F Boeve3, Dag Aarsland4.   

Abstract

The broad importance of dementia is undisputed, with Alzheimer's disease justifiably getting the most attention. However, dementia with Lewy bodies and Parkinson's disease dementia, now called Lewy body dementias, are the second most common type of degenerative dementia in patients older than 65 years. Despite this, Lewy body dementias receive little attention and patients are often misdiagnosed, leading to less than ideal management. Over the past 10 years, considerable effort has gone into improving diagnostic accuracy by refining diagnostic criteria and using imaging and other biomarkers. Dementia with Lewy bodies and Parkinson's disease dementia share the same pathophysiology, and effective treatments will depend not only on successful treatment of symptoms but also on targeting the pathological mechanisms of disease, ideally before symptoms and clinical signs develop. We summarise the most pertinent progress from the past 10 years, outlining some of the challenges for the future, which will require refinement of diagnosis and clarification of the pathogenesis, leading to disease-modifying treatments.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26595642      PMCID: PMC5792067          DOI: 10.1016/S0140-6736(15)00462-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  156 in total

1.  Multimodality imaging characteristics of dementia with Lewy bodies.

Authors:  Kejal Kantarci; Val J Lowe; Bradley F Boeve; Stephen D Weigand; Matthew L Senjem; Scott A Przybelski; Dennis W Dickson; Joseph E Parisi; David S Knopman; Glenn E Smith; Tanis J Ferman; Ronald C Petersen; Clifford R Jack
Journal:  Neurobiol Aging       Date:  2011-10-21       Impact factor: 4.673

Review 2.  Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment.

Authors:  Per Svenningsson; Eric Westman; Clive Ballard; Dag Aarsland
Journal:  Lancet Neurol       Date:  2012-08       Impact factor: 44.182

3.  Pattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies.

Authors:  Zuzana Nedelska; Tanis J Ferman; Bradley F Boeve; Scott A Przybelski; Timothy G Lesnick; Melissa E Murray; Jeffrey L Gunter; Matthew L Senjem; Prashanti Vemuri; Glenn E Smith; Yonas E Geda; Jonathan Graff-Radford; David S Knopman; Ronald C Petersen; Joseph E Parisi; Dennis W Dickson; Clifford R Jack; Kejal Kantarci
Journal:  Neurobiol Aging       Date:  2014-07-15       Impact factor: 4.673

4.  Nonamnestic mild cognitive impairment progresses to dementia with Lewy bodies.

Authors:  Tanis J Ferman; Glenn E Smith; Kejal Kantarci; Bradley F Boeve; V Shane Pankratz; Dennis W Dickson; Neill R Graff-Radford; Zbigniew Wszolek; Jay Van Gerpen; Ryan Uitti; Otto Pedraza; Melissa E Murray; Jeremiah Aakre; Joseph Parisi; David S Knopman; Ronald C Petersen
Journal:  Neurology       Date:  2013-11-08       Impact factor: 9.910

5.  Cognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies.

Authors:  J A Schneider; Z Arvanitakis; L Yu; P A Boyle; S E Leurgans; D A Bennett
Journal:  Brain       Date:  2012-10       Impact factor: 13.501

6.  Treatment outcomes in REM sleep behavior disorder.

Authors:  Stuart J McCarter; Christopher L Boswell; Erik K St Louis; Lucas G Dueffert; Nancy Slocumb; Bradley F Boeve; Michael H Silber; Eric J Olson; Maja Tippmann-Peikert
Journal:  Sleep Med       Date:  2013-01-23       Impact factor: 3.492

Review 7.  Recommendations of the Alzheimer's disease-related dementias conference.

Authors:  Thomas J Montine; Walter J Koroshetz; Debra Babcock; Dennis W Dickson; Wendy R Galpern; M Maria Glymour; Steven M Greenberg; Michael L Hutton; David S Knopman; Andrey N Kuzmichev; Jennifer J Manly; Karen S Marder; Bruce L Miller; Creighton H Phelps; William W Seeley; Beth-Anne Sieber; Nina B Silverberg; Margaret Sutherland; Christine L Torborg; Salina P Waddy; Berislav V Zlokovic; Roderick A Corriveau
Journal:  Neurology       Date:  2014-07-30       Impact factor: 9.910

8.  Cerebrospinal fluid α-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort.

Authors:  Tessandra Stewart; Changqin Liu; Carmen Ginghina; Kevin C Cain; Peggy Auinger; Brenna Cholerton; Min Shi; Jing Zhang
Journal:  Am J Pathol       Date:  2014-03-11       Impact factor: 4.307

Review 9.  LRRK2 as a Potential Genetic Modifier of Synucleinopathies: Interlacing the Two Major Genetic Factors of Parkinson's Disease.

Authors:  Cheol Hwan Hyun; Chae Young Yoon; He-Jin Lee; Seung-Jae Lee
Journal:  Exp Neurobiol       Date:  2013-12-31       Impact factor: 3.261

10.  Neurodegenerative disorder risk in idiopathic REM sleep behavior disorder: study in 174 patients.

Authors:  Alex Iranzo; Ana Fernández-Arcos; Eduard Tolosa; Mónica Serradell; José Luis Molinuevo; Francesc Valldeoriola; Ellen Gelpi; Isabel Vilaseca; Raquel Sánchez-Valle; Albert Lladó; Carles Gaig; Joan Santamaría
Journal:  PLoS One       Date:  2014-02-26       Impact factor: 3.240

View more
  118 in total

Review 1.  Biomarkers for neurodegenerative diseases.

Authors:  Oskar Hansson
Journal:  Nat Med       Date:  2021-06-03       Impact factor: 53.440

Review 2.  Clinical drug development for dementia with Lewy bodies: past and present.

Authors:  Garam Lee; Jeffrey Cummings; Boris Decourt; James B Leverenz; Marwan N Sabbagh
Journal:  Expert Opin Investig Drugs       Date:  2019-10-28       Impact factor: 6.206

3.  The costs of dementia subtypes to California Medicare fee-for-service, 2015.

Authors:  Yingjia Chen; Leslie Wilson; John Kornak; R Adams Dudley; Jennifer Merrilees; Stephen J Bonasera; Christie M Byrne; Kirby Lee; Winston Chiong; Bruce L Miller; Katherine L Possin
Journal:  Alzheimers Dement       Date:  2019-06-04       Impact factor: 21.566

4.  Further Thoughts on Antipsychotics in Dementia with Lewy Bodies.

Authors:  Joseph H Friedman
Journal:  Mov Disord Clin Pract       Date:  2016-07-12

5.  Association of arterial stiffness with cognition in patients with Lewy body disorder.

Authors:  Dong-Woo Ryu; Joong-Seok Kim; Jee-Eun Lee; Jeong-Wook Park; Yoon-Sang Oh; Jae-Young An; Kwang-Soo Lee
Journal:  Neurol Sci       Date:  2017-05-05       Impact factor: 3.307

Review 6.  Assessment and Management of Neuropsychiatric Symptoms in Parkinson's Disease.

Authors:  Christoph Mueller; Anto P Rajkumar; Yi Min Wan; Latha Velayudhan; Dominic Ffytche; Kallol Ray Chaudhuri; Dag Aarsland
Journal:  CNS Drugs       Date:  2018-07       Impact factor: 5.749

Review 7.  The missing link between sleep disorders and age-related dementia: recent evidence and plausible mechanisms.

Authors:  Feng Zhang; Rujia Zhong; Song Li; Raymond Chuen-Chung Chang; Weidong Le
Journal:  J Neural Transm (Vienna)       Date:  2017-02-10       Impact factor: 3.575

Review 8.  Role of Neuroimaging on Differentiation of Parkinson's Disease and Its Related Diseases.

Authors:  Toshihide Ogawa; Shinya Fujii; Keita Kuya; Shin-Ichiro Kitao; Yuki Shinohara; Mana Ishibashi; Yoshio Tanabe
Journal:  Yonago Acta Med       Date:  2018-09-26       Impact factor: 1.641

9.  The Italian dementia with Lewy bodies study group (DLB-SINdem): toward a standardization of clinical procedures and multicenter cohort studies design.

Authors:  L Bonanni; A Cagnin; F Agosta; C Babiloni; B Borroni; M Bozzali; A C Bruni; M Filippi; D Galimberti; R Monastero; C Muscio; L Parnetti; D Perani; L Serra; V Silani; P Tiraboschi; A Padovani
Journal:  Neurol Sci       Date:  2016-09-13       Impact factor: 3.307

10.  Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort.

Authors:  Inger van Steenoven; Dag Aarsland; Daniel Weintraub; Elisabet Londos; Frédéric Blanc; Wiesje M van der Flier; Charlotte E Teunissen; Brit Mollenhauer; Tormod Fladby; Milica G Kramberger; Laura Bonanni; Afina W Lemstra
Journal:  J Alzheimers Dis       Date:  2016-08-18       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.